3
A RUDN University chemist created anti-tumour compounds that are up to 80 times more effective than their counterparts

A RUDN University chemist created anti-tumour compounds that are up to 80 times more effective than their counterparts

A chemist from RUDN University has created platinum complex compounds that are superior in activity to cisplatin, the drug for the treatment of tumour diseases. The new compounds turned out to be also less toxic to healthy cells.

Platinum-based anticancer drugs — cisplatin, oxaliplatin, and carboplatin — are used for chemotherapy in about half of cancer cases. They penetrate cells and interact with DNA molecules. The process is fatal for rapidly dividing cancer cells because the drugs prevent the duplication of DNA molecules, which is necessary for successful division. Since cancer cells divide rapidly, they are the first to be affected. Still, platinum derivatives have certain disadvantages: low stability under physiological conditions and high toxicity.

To create new drugs, a strategy that involves the development of hybrid molecules is often used in modern chemistry. Such substances consist of two or more active fragments that are linked by a linker into one molecule. They usually have a double action, characteristic of each of the fragments.

A chemist from RUDN University, candidate of biological sciences Kirill Kirsanov, created a series of new drugs: hybrids of cisplatin, lonidamine, and bexarotene. Lonidamine itself has an anti-tumour effect due to its ability to suppress energy metabolism in cancer cells. In combination with radiation therapy, it is used to treat brain tumours. Bexarotene is used for the treatment of lung cancer and breast cancer, as it inhibits the growth of tumour cells of hematopoietic and squamous origin.

A derivative of cisplatin with bexarotene turned out to be the most promising. A combination of succinic acid and ethylenediamine was used as a linker. In tests conducted on four tumour cell lines, the hybrid drug was 80 times more active than bexaroten and 20 times higher on average than cisplatin, and the new drug was 80 times more active than cisplatin on MCF7D cell line. Based on the resulting leading compound, new and more effective anti-tumour medications can be developed.

The paper was published in the journal Inorganica Chimica Acta

Scientific Conferences View all
03 Nov 2017
RUDN University organized the first 5G Summit R&D Russia on June 19 - 20, 2017
1787
International scientific cooperation View all
03 Nov 2017
The main goal of the RUDN University and UNISDR Office for Northeast Asia and Global Education and Training Institute for Disaster Risk Reduction at Incheon (UNISDR ONEA-GETI) cooperation is to obtain knowledge about disaster risk reduction and international experience in this area for creating training courses for basic and additional professional education in RUDN
1390
Similar newsletter View all
07 Jul
RUDN University Biologist: salted water saves fish from stress when transporting

RUDN University biologist with colleagues from Brazil and Iran found how to alleviate the stress of fish during transportation. It turned out that this can be achieved with salted water.

62
20 Apr
RUDN University agronomists increased wheat yield by 65%

RUDN University agronomists have proposed a new scheme for fertilizing winter wheat, which allows increasing the yield by 68%. The key to this is in the combination of nitrogen and growth regulators.

124
20 Apr
RUDN Biologists Study Live Microorganisms in Toxic Liquids for Metalworking

RUDN biologists have studied microorganisms that can survive in metalworking fluids. The results will allow “picking up” bacteria and fungi that can process toxic waste fluids into a harmless product.

118
Similar newsletter View all